Metastatic Squamous Neck Cancer With Occult Primary - 25 Studies Found
Terminated |
: Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer :
|
Completed |
: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck :
|
Completed |
: Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer :
|
Completed |
: Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer :
|
Completed |
: Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer :
|
Completed |
: Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck :
|
Completed |
: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer :
|
Active, not recruiting |
: Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck :
|
Suspended |
: Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer :
|